Page 3 - License Application News Today

Moderna anticipates initial regulatory approvals for its RSV vaccine in first half of 2024.

/PRNewswire/ -- The "Europe Gene Editing Technologies Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.coms offering. The...

NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Bi...

This story was first published on the Benzinga India portal. Elon Musk’s Starlink satellite network, aiming for a 2024 launch in India, might face delays in obtaining its license due to complications similar to those encountered by Verizon Communications (NYSE: VZ) in a previous case. This development could hinder Starlink’s timely entry into the Indian market. What Happened? The primary issue causing the delay is the Indian government’s requirement for complete disclosure o...

Obtained clarity from U.S. Food and Drug Administration on next steps to advance ONS-5010NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the...

Are you ready to hit the road and get behind the wheel? The first step towards

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our December 2023 month-in-review features a recap of This Year in Medicine, the latest updates to the ophthalmic pipeline, and the newest episode of our KOL-led podcast series.

Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for...

Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application ...

Based on the special protocol assessment submission, the company expects to begin the non-inferiority trial for the ophthalmic bevacizumab in the first quarter of 2024.